NCT06337695View on ClinicalTrials.gov

VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

298

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

December 1, 2026

Conditions

CancerCancer Metastatic

Interventions

BIOLOGICAL

Vedolizumab

300 mg IV at weeks 0, 3, 6, 14, and 22

BIOLOGICAL

Placebo

300 mg IV at weeks 0, 3, 6, 14, and 22

All Listed Sponsors

lead

University of Calgary

OTHER